Drug intelligence / Profile preview

isorhamnetin

Development stage
Preclinical
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral
01

Overview

Isorhamnetin is a naturally occurring flavonol aglycone and a methylated metabolite of quercetin. It is found in various plants such as Hippophae rhamnoides (sea buckthorn) and Ginkgo biloba. Isorhamnetin exhibits multiple pharmacological activities including antioxidant, anti-inflammatory, anti-tumor, anti-viral, and organ-protective effects. Its mechanisms of action involve modulation of several signaling pathways such as Phosphatidylinositol 3-kinase/Protein kinase B (Akt)/mammalian target of rapamycin (mTOR), Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), Mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK1/2), and Nuclear factor erythroid-derived 2-like 2 (Nrf2)/Heme oxygenase-1 (HO-1). Isorhamnetin has been shown to inhibit cell proliferation and induce apoptosis in various cancer cell lines by targeting these pathways. It also demonstrates protective effects against cardiovascular diseases by reducing oxidative stress and inflammation[3][4][6][8]. The compound inhibits the expression of CYP1B1 enzyme and can modulate endothelial function through its antioxidant properties[4][5]. While widely studied for its therapeutic potential in preclinical models for conditions like cancer (colon cancer, gastric cancer), cardiovascular disease (atherosclerosis), diabetes-related complications, neurodegenerative injury protection, obesity prevention and more[3][6], it has not been approved as a pharmaceutical drug.

Other names
3'-methoxy-3,4',5,7-tetrahydroxyflavoneisorhamnetine
02

Targets

ATM (Ataxia telangiectasia mutated protein)AKT (RAC-alpha serine/threonine-protein kinase)CYP1B1 (Cytochrome P450 1B1)NF-κBNFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)VEGFR (VEGFR family)

Beyond the preview

Go deeper on isorhamnetin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on isorhamnetin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call